Loading viewer...
earnings
Format: PDF earnings
Moderna's first quarter 2023 earnings presentation covering financial results, business review, and forward-looking guidance. The presentation discusses anticipated COVID-19 vaccine sales, preparations for RSV and flu vaccine launches in 2024, and clinical trial timelines for respiratory and oncology programs including individualized neoantigen therapy.
conference
25 Pages
earnings
75 Pages
TUI Group
AIA Engineering Q4 FY2019 Earnings Presentation
earningsearnings
11 Pages
AIA Engineering Limited
BlueScope Steel 1H FY2023 Financial Results
earningsearnings
92 Pages
BlueScope Steel Limited